MedTrace Logo

Caffeine and Training Intensity Quantification

NCT06210984 · Status: NOT_YET_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 36

Last updated 2024-01-18

No results posted yet for this study

Summary

The goal of this clinical trial is to learn about the effects of caffeine on exercise physiology and the subsequent quantification of athlete training zones in trained cyclists. The main questions that it aims to answer are:

* What are the effects of low and moderate doses of caffeine on exercise physiology.
* How do the effects of caffeine on exercise physiology affect the calculation of training zones.
* Do the effects of caffeine on exercise physiology differ between men and women.

Participants will complete four trials on a cycle ergometer as follows:

* Trial 1: participants will complete two incremental tests to determine the power outputs required to elicit 50-80% of maximal oxygen consumption for trials 2-4.
* Trials 2-4: participants will consume (in a randomized order) either a low (2 mg/kg) dose of caffeine, a moderate (5 mg/kg) dose of caffeine, or a placebo (maltodextrin), 45 minutes prior to to completing an incremental cycling test from 50-80% of maximal oxygen uptake.

Measures of heart rate, oxygen uptake, blood lactate, and perceived exertion will be recorded throughout all trials.

Researchers will compare the effects of exercise intensity, caffeine dose, and sex to see if they affect exercise physiology and training zone quantification.

Conditions

  • Caffeine

Interventions

DRUG

Low caffeine dose

2 mg/kg dose of caffeine in pill form

DRUG

Moderate caffeine dose

5 mg/kg dose of caffeine in pill form

DRUG

Placebo

5 mg/kg dose of maltodextrin in pill form

Sponsors & Collaborators

  • St. Mary's University, Twickenham

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2024-01-31
Primary Completion
2025-12-31
Completion
2025-12-31

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06210984 on ClinicalTrials.gov